13007-32-4

13007-32-4 structure

Name: Lacto-N-neotetraose
Chemical Name: β-D-Gal-(1→4)-β-D-GlcNAc-(1→3)-β-D-Gal-(1→4)-D-Glc
CAS Number: 13007-32-4
Molecular Formula: C₂₆H₄₅NO₂₁
Molecular Weight: 707.63000
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-03-30 08:00:00
Modify Date: 2024-01-06 17:54:06
Lacto-N-neotetraose (LNnT) is an endogenous metabolite. Lacto-N-neotetraose can inhibit TNF-α induced IL-8 secretion in immature epithelial cells. Lacto-N-neotetraose has anti-inflammatory avtivity, and can improve the wound closure[1][2][4].

Name	β-D-Gal-(1→4)-β-D-GlcNAc-(1→3)-β-D-Gal-(1→4)-D-Glc
Synonyms	LACTO-N-NEOTETRAOSE Lacto-N-neo-tetraose beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc

Description	Lacto-N-neotetraose (LNnT) is an endogenous metabolite. Lacto-N-neotetraose can inhibit TNF-α induced IL-8 secretion in immature epithelial cells. Lacto-N-neotetraose has anti-inflammatory avtivity, and can improve the wound closure[1][2][4].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	Endogenous Metabolite[1], TNFR1[2].
In Vitro	Lacto-N-neotetraose (5 mg/mL, 24 h) induces IL-8 secretion in T84 cells[2]. Lacto-N-neotetraose (5 mg/mL, 24 h) reduces TNF-α induced IL-8-secretion with 38% in FHs 74 Int cells[2]. Lacto-N-neotetraose binds TNFR1 (Tumor necrosis factor receptor 1) with a Kd value of 900 ± 660 nM[2]. Lacto-N-neotetraose (5 mg/mL, 24 h) attenuates TNF-α induced inflammation by TNFR1 ectodomain shedding in FHs 74 Int cells[2].
In Vivo	Lacto-N-neotetraose (100 μM, intratracheal administration for 24 h) reduces the abundance of Streptococcus pneumonia in the lungs of pneumonia rabbits[3]. Lacto-N-neotetraose (100/200 μg, Intradermal injection, at 3, 7, 14, and 21 days post-surgery) increases the wound closure rate on day 7 post-wounding[4]. Animal Model: Rabbit model of pneumonia[3] Dosage: 100 μM Administration: Intratracheal administration for 24 h Result: Decreased by ~2 logs the bacterial load in the lung at 48 h after challenge. Eliminated the extensive, edematous right middle lobe lesion evident at 48 h in control animals. Animal Model: Mice with symmetric full-thickness wounds Dosage: 100, 200 μg Administration: Intradermal injection, at 3, 7, 14, and 21 days post-surgery. Result: Exhibited better healing score, follicle formation, and lower epidermal thickness index (H&E staining).
References	[1]. Xiaomin Dong, et al. CRISPRi-Guided Multiplexed Fine-Tuning of Metabolic Flux for Enhanced Lacto- N-neotetraose Production in Bacillus subtilis. J Agric Food Chem. 2020 Feb 26;68(8):2477-2484. [2]. Lianghui Cheng, et al. The Human Milk Oligosaccharides 3-FL, Lacto-N-Neotetraose, and LDFT Attenuate Tumor Necrosis Factor-α Induced Inflammation in Fetal Intestinal Epithelial Cells In Vitro through Shedding or Interacting with Tumor Necrosis Factor Receptor 1. Mol Nutr Food Res. 2021 Apr;65(7):e2000425. [3]. I Idänpään-Heikkilä, et al. Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia. J Infect Dis. 1997 Sep;176(3):704-12. [4]. Behrouz Farhadihosseinabadi, et al. The in vivo effect of Lacto-N-neotetraose (LNnT) on the expression of type 2 immune response involved genes in the wound healing process. Sci Rep. 2020 Jan 22;10(1):997.

Density	1.72g/cm3
Boiling Point	1173.6ºC at 760mmHg
Molecular Formula	C₂₆H₄₅NO₂₁
Molecular Weight	707.63000
Flash Point	663.6ºC
Exact Mass	707.24800
PSA	356.70000
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.668
Storage condition	2-8°C

RIDADR	NONH for all modes of transport
WGK Germany	3

13007-32-4	86594-19-6
75645-27-1	64003-55-0
68124-22-1	221224-60-8
67319-96-4	56501-25-8
60254-64-0	30517-76-1